AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2008283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 0.06 meq/ml sodium bicarbonate (LPH)
Number of subjects: 80
Study 2008283 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (L)
Number of subjects: 80
Study 2008283 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine (LE)
Number of subjects: 80
Study 2008283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine and 0.06 meq/ml sodium bicarbonate (LEPH)
Number of subjects: 80
Study 205828 — intervention group
Group type: EXPERIMENTAL
Intervention: p-aminosalicylic acid (PAS) 150 mg/kg/day
Number of subjects: 20
Study 30053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant consumption
Number of subjects: 655
Study 30053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 655
Study 30053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorders (vs. schizophrenia)
Number of subjects: 655
Study 30053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 655
Study 30053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MCSI psychotic score
Number of subjects: 655
Study 27651513 — intervention group
Group type: COMPARATOR
Intervention: Simple Continuous Infusion
Number of subjects: 0
Study 27651513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Boluses
Number of subjects: 0
Study 25595234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolt-on dimensions for vision problems, hearing problems, and tiredness
Number of subjects: 300
Study 25595234 — intervention group
Group type: COMPARATOR
Intervention: Core EQ-5D states without bolt-on dimensions
Number of subjects: 300
Study 23250000 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard obesity rehabilitation plus combined planning and telephone aftercare intervention (6 phone calls for 6 months)
Number of subjects: 467
Study 23250000 — intervention group
Group type: COMPARATOR
Intervention: Standard obesity rehabilitation
Number of subjects: 467
Study 21168113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma massage
Number of subjects: 0
Study 21168113 — intervention group
Group type: COMPARATOR
Intervention: Plain massage
Number of subjects: 0
Study 21168113 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19720635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 1507
Study 17556604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 500
Study 17556604 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine + Pyrimethamine (CQ + P)
Number of subjects: 500
Study 27118470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 60
Study 27118470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Number of subjects: 60
Study 27118470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg)
Number of subjects: 60
Study 27118470 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study 27118470 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Aspirin 300 mg, Aspirin 75 mg, Clopidogrel)
Number of subjects: 60
Study 27118470 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 11879344 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 242
Study 11879344 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 242
Study 9444449 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro in combination with NPH human insulin administered twice daily
Number of subjects: 707
Study 9444449 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin in combination with NPH human insulin administered twice daily
Number of subjects: 707
Study 7944443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Number of subjects: 21
Study 7944443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy and coagulation therapy for remaining tumor
Number of subjects: 21
Study 7944443 — intervention group
Group type: COMPARATOR
Intervention: Coagulation therapy only
Number of subjects: 21
Study 3555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (verapamil 120 mg three times a day and atenolol 100 mg once a day)
Number of subjects: 15
Study 3555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times a day
Number of subjects: 15
Study 3555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 15
Study 3555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 15
Study 3555566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31846169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic activation of intracanal‐heated NaOCl (group B)
Number of subjects: 18
Study 31846169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic activation (group A)
Number of subjects: 18
Study 31846169 — intervention group
Group type: COMPARATOR
Intervention: Syringe-and-needle irrigation (group C)
Number of subjects: 18
Study 30300557 — intervention group
Group type: EXPERIMENTAL
Intervention: S/F Easyhaler
Number of subjects: 227
Study 30300557 — intervention group
Group type: COMPARATOR
Intervention: Seretide Diskus
Number of subjects: 227
Study 28780395 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO (robotic seal)
Number of subjects: 415
Study 28780395 — intervention group
Group type: EXPERIMENTAL
Intervention: Plush toy
Number of subjects: 415
Study 28780395 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 26255172 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP) plus Acceptance and Commitment Therapy (ACT)
Number of subjects: 59
Study 26255172 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 59
Study 23954534 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids with prompt delivery (PD group) after 48 hours
Number of subjects: 267
Study 23954534 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids and expectant management (EXM group)
Number of subjects: 267
Study 23954534 — intervention group
Group type: COMPARATOR
Intervention: Steroids with prompt delivery (PD group)
Number of subjects: 267
Study 21367563 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (IB)
Number of subjects: 60
Study 21367563 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anesthesia (C)
Number of subjects: 60
Study 18799288 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine 50 mg once-weekly
Number of subjects: 50
Study 18799288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16537563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix with OC pretreatment
Number of subjects: 182
Study 16537563 — intervention group
Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 182
Study 12660671 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Treadmill Score (DTS)
Number of subjects: 6251
Study 12660671 — intervention group
Group type: EXPERIMENTAL
Intervention: Veteran Affairs Medical Center Score (VAMCS)
Number of subjects: 6251
Study 12660671 — intervention group
Group type: EXPERIMENTAL
Intervention: GISSI-2 Index
Number of subjects: 6251
Study 11591552 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited stair climbing
Number of subjects: 83
Study 9390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (days 3-5)
Number of subjects: 157
Study 9390483 — intervention group
Group type: EXPERIMENTAL
Intervention: Late tracheostomy (days 10-14)
Number of subjects: 157
Study 9390483 — intervention group
Group type: COMPARATOR
Intervention: Continued endotracheal intubation
Number of subjects: 157
Study 7946102 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine once every month
Number of subjects: 121
Study 7946102 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 121
Study 7946102 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 121
Study 2895374 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians examining patients with respiratory signs
Number of subjects: 24
Study 2895374 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence or absence of respiratory signs
Number of subjects: 24
Study 2895374 — intervention group
Group type: EXPERIMENTAL
Intervention: Differing from majority on signs
Number of subjects: 24
Study 29606011 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Beat Acupunch (HBA) regimen, 40-min session, 3 times per week for 6 months
Number of subjects: 228
Study 29606011 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 228
Study 31340542 — intervention group
Group type: EXPERIMENTAL
Intervention: IoT-based monitoring using a Wireless Sensor Kit for behavioral aspects (bed/rest patterns, toilet usage, room presence)
Number of subjects: 0
Study 31340542 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression framework for detecting trends and labeling anomalies
Number of subjects: 0
Study 31340542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud-based analytics services for automatic extraction of relevant information from raw sensor data streams
Number of subjects: 0
Study 28100438 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/kg rifampicin per day with isoniazid, pyrazinamide, and ethambutol
Number of subjects: 365
Study 28100438 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Number of subjects: 365
Study 28100438 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Number of subjects: 365
Study 28100438 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and moxifloxacin
Number of subjects: 365
Study 28100438 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol)
Number of subjects: 365
Study 25403587 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed dose)
Number of subjects: 596
Study 25403587 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (weight-based)
Number of subjects: 596
Study 25403587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both subcutaneous and intravenous trastuzumab
Number of subjects: 596
Study 23234805 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 10mg/day plus carboplatin and paclitaxel
Number of subjects: 120
Study 23234805 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 120
Study 21813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 0
Study 21813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diethylcarbamazine and albendazole (DEC/ALB)
Number of subjects: 0
Study 21813840 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ALB)
Number of subjects: 0
Study 19076157 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg at 22.00 h every night
Number of subjects: 20
Study 16673379 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral radiofrequency energy (RF) collagen micro-remodeling
Number of subjects: 173
Study 16673379 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 173
Study 15112170 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 400 mg, thrice daily the day before and day of the contrast procedure
Number of subjects: 91
Study 15112170 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 91
Study 10782553 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-orientated group therapy
Number of subjects: 32
Study 10782553 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy group
Number of subjects: 32
Study 9133220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine test
Number of subjects: 17
Study 9133220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral guanfacine test
Number of subjects: 17
Study 1404350 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation for 4 weeks
Number of subjects: 31
Study 1404350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 4027785 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard techniques for graft handling
Number of subjects: 77
Study 4027785 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing gloves before preclotting the graft
Number of subjects: 77
Study 4027785 — intervention group
Group type: EXPERIMENTAL
Intervention: Established graft infection
Number of subjects: 77
Study 31547214 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 63
Study 31547214 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 63
Study 29935086 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 164
Study 29935086 — intervention group
Group type: COMPARATOR
Intervention: Assessment-Only (AO) Control
Number of subjects: 164
Study 26700096 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day of fish oil (0.6 g/day of EPA and DHA) for 9 weeks
Number of subjects: 30
Study 26700096 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received neither fish oil nor placebo
Number of subjects: 30
Study 25283757 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (video, brochure, questionnaire)
Number of subjects: 319
Study 25283757 — intervention group
Group type: COMPARATOR
Intervention: Control (brochure only)
Number of subjects: 319
Study 22763392 — intervention group
Group type: EXPERIMENTAL
Intervention: MoleMate system (SIAscopy with primary care scoring algorithm)
Number of subjects: 1297
Study 22763392 — intervention group
Group type: EXPERIMENTAL
Intervention: MoleMate system
Number of subjects: 1297
Study 22763392 — intervention group
Group type: COMPARATOR
Intervention: Best practice alone (control group)
Number of subjects: 1297
Study 20582542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional parecoxib (40 mg IV 30 min before skin incision)
Number of subjects: 41
Study 20582542 — intervention group
Group type: COMPARATOR
Intervention: Postincisional parecoxib (40 mg IV 30 min after skin incision)
Number of subjects: 41
Study 20582542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received patient-controlled analgesia (PCA) morphine
Number of subjects: 41
Study 17394704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 40
Study 17394704 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 15679759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.d.
Number of subjects: 0
Study 15679759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12358621 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin (40 mg/kg over 3 days) plus placebo chloroquine
Number of subjects: 240
Study 12358621 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days) plus placebo artemisinin
Number of subjects: 240
Study 10366800 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF plus G-CSF
Number of subjects: 102
Study 10366800 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 102
Study 9723152 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (D-FEN)
Number of subjects: 28
Study 1928212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine
Number of subjects: 0
Study 6412223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 6412223 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study 30256314 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Russia alone
Number of subjects: 3075
Study 30256314 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Russia with OPV
Number of subjects: 3075
Study 30256314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination before 28 days)
Number of subjects: 3075
Study 29603114 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine labor epidural analgesia (EA)
Number of subjects: 488
Study 29603114 — intervention group
Group type: COMPARATOR
Intervention: Pain relief on maternal request only (Control)
Number of subjects: 488
Study 26661521 — intervention group
Group type: EXPERIMENTAL
Intervention: 940-nm EVLA
Number of subjects: 142
Study 26661521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1470-nm EVLA
Number of subjects: 142
Study 24740484 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous functional electrical stimulation (FES); 15 children, 15-minute sessions, 3 times per week for 15 courses
Number of subjects: 30
Study 24740484 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation; 15 children
Number of subjects: 30
Study 23074206 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04523655 3‐mg intravitreal injections
Number of subjects: 184
Study 23074206 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04523655 0.4‐mg intravitreal injections
Number of subjects: 184
Study 23074206 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04523655 1‐mg intravitreal injections
Number of subjects: 184
Study 23074206 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 184
Study 20925948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored home-based exercise twice weekly
Number of subjects: 210
Study 20925948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise twice weekly in rehabilitation center
Number of subjects: 210
Study 20925948 — intervention group
Group type: COMPARATOR
Intervention: Usual care and information of exercise and nutrition (Control)
Number of subjects: 210
Study 18410585 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg melatonin and 100 mg SB‐73
Number of subjects: 145
Study 18410585 — intervention group
Group type: COMPARATOR
Intervention: 200 mg Acyclovir
Number of subjects: 145
Study 16103288 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic copolymer staple-line reinforcement sleeves
Number of subjects: 34
Study 16103288 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement (control group)
Number of subjects: 34
Study 11962225 — intervention group
Group type: EXPERIMENTAL
Intervention: Back education program for intervention children
Number of subjects: 706
Study 10636595 — intervention group
Group type: EXPERIMENTAL
Intervention: nSIPPV
Number of subjects: 11
Study 10636595 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 11
Study 7488479 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 1.0 (group O)
Number of subjects: 34
Study 7488479 — intervention group
Group type: COMPARATOR
Intervention: FIO2 of 0.35 (group A)
Number of subjects: 34
Study 1957409 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg, supplemented with half of the initial dosage if necessary)
Number of subjects: 100
Study 1957409 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg, supplemented with half of the initial dosage if necessary)
Number of subjects: 100
Study 1957409 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 7343284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU heparin-dihydroergotamine mesylate (Dihydergot)
Number of subjects: 107
Study 7343284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 31674810 — intervention group
Group type: EXPERIMENTAL
Intervention: HTC (hyperventilation + thigh-cuff deflation)
Number of subjects: 19
Study 31674810 — intervention group
Group type: COMPARATOR
Intervention: Con (control transition)
Number of subjects: 19
Study 31674810 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-cuff deflation
Number of subjects: 19
Study 27819489 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (1 mg kg‐1 per 12 hours for 5 days)
Number of subjects: 48
Study 27819489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 26449164 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 48 weeks followed by treatment interruption (TI)
Number of subjects: 0
Study 26449164 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell exhaustion markers (PD-1, Tim-3, Lag-3) measured prior to ART
Number of subjects: 0
Study 23726041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg
Number of subjects: 212
Study 23726041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg
Number of subjects: 212
Study 23726041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 500 mg
Number of subjects: 212
Study 23726041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 23726041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (all doses)
Number of subjects: 212
Study 21376885 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation questionnaire
Number of subjects: 30
Study 21376885 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-prevention questionnaire
Number of subjects: 30
Study 21376885 — intervention group
Group type: COMPARATOR
Intervention: Familiarization flight (control group)
Number of subjects: 30
Study 19711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) levels of 140-150 mmHg
Number of subjects: 22576
Study 19711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) levels > 150 - < or = 160 mmHg
Number of subjects: 22576
Study 19711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) levels > 160 mmHg
Number of subjects: 22576
Study 19711440 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina reported in the 4 weeks prior to a protocol visit
Number of subjects: 22576